Expand BHVN Menu
BHVN MENU

BHVN Latest Press Releases

-- January 12, 2026 --

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference PRNewswire 11:15 AM

-- January 7, 2026 --

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 PRNewswire 7:00 AM

-- December 24, 2025 --

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder PRNewswire 1:00 PM

-- December 11, 2025 --

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress PRNewswire 7:00 AM

-- November 13, 2025 --

Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M PRNewswire 4:05 PM

-- November 12, 2025 --

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares PRNewswire 7:15 AM

-- November 11, 2025 --

Biohaven Announces Proposed Public Offering of Common Shares PRNewswire 4:05 PM

-- November 10, 2025 --

Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments PRNewswire 6:58 AM

-- November 4, 2025 --

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia PRNewswire 8:06 PM
Market Data Delayed 15 Minutes